Literature DB >> 17855736

Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?

P J Van der Linden1, J-F Hardy, A Daper, A Trenchant, S G De Hert.   

Abstract

BACKGROUND: Aprotinin, a non-specific serine protease inhibitor, has been used for two decades to reduce perioperative blood loss and the risk for allogeneic transfusion in cardiac surgery. This study evaluated the effects of aprotinin on outcome (mortality, cardiac events, renal failure, and cerebrovascular events) in such patients undergoing cardiac surgery with cardiopulmonary bypass.
METHODS: Data were obtained in patients who received a strict blood conservation protocol: no antifibrinolytic therapy when at low risk (n = 854) and aprotinin (n = 1210) when at high risk for blood transfusion. Relative risk of different pre- and intra-operative variables was calculated for the different outcome variables. Backward stepwise logistic regression analysis was used to identify the independent risk factors associated with the different outcome variables. Statistical significance was accepted at P < 0.01.
RESULTS: Postoperative mortality and morbidity were higher in the aprotinin group but this was related to an increased incidence of perioperative risk factors. Mortality was similar to that predicted by the Euroscore. Complex surgery was the only independent variable associated with postoperative cardiac events. Preoperative heart failure, preoperative creatinine > 1.5 mg dl(-1), urgent, and redo surgery were the independent variables associated with postoperative haemodialysis. Age > 70 yr was identified as the only independent variable associated with neurologic dysfunction.
CONCLUSIONS: In the present study, patients receiving aprotinin as part of a strict blood conservation strategy represent a population at high risk for postoperative complications. For the outcome variables studied, aprotinin administration was not identified as an independent risk factor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855736     DOI: 10.1093/bja/aem252

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

Review 1.  Perfusion vs. oxygen delivery in transfusion with "fresh" and "old" red blood cells: the experimental evidence.

Authors:  Amy G Tsai; Axel Hofmann; Pedro Cabrales; Marcos Intaglietta
Journal:  Transfus Apher Sci       Date:  2010-06-19       Impact factor: 1.764

2.  Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era.

Authors:  Stacia M DeSantis; J Matthew Toole; John M Kratz; Walter E Uber; Margaret J Wheat; Martha R Stroud; John S Ikonomidis; Francis G Spinale
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

3.  Use and outcomes of antifibrinolytic therapy in patients undergoing cardiothoracic surgery at 20 academic medical centers in the United States.

Authors:  Karl Matuszewski; Robert Schoenhaus; Mary Ellen Bonk; James Lane; Michael Oinonen
Journal:  P T       Date:  2008-02

4.  Alterations in plasma soluble vascular endothelial growth factor receptor-1 (sFlt-1) concentrations during coronary artery bypass graft surgery: relationships with post-operative complications.

Authors:  Yves Denizot; Alexandre Leguyader; Elisabeth Cornu; Marc Laskar; Isabelle Orsel; Christelle Vincent; Nathalie Nathan
Journal:  J Cardiothorac Surg       Date:  2008-04-18       Impact factor: 1.637

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.